Yair Lotan Selected Research

Cystectomy

8/2022	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
4/2022	The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis.
1/2022	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
1/2022	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
1/2022	Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
1/2022	Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
1/2022	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer.
12/2021	Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival.
11/2021	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
11/2021	Metastasis-directed radiation therapy after radical cystectomy for bladder cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yair Lotan Research Topics

Disease

175	Neoplasms (Cancer) 06/2022 - 01/2002
156	Urinary Bladder Neoplasms (Bladder Cancer) 11/2022 - 01/2002
144	Carcinoma (Carcinomatosis) 08/2022 - 02/2004
51	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 06/2004
28	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2004
26	Non-Muscle Invasive Bladder Neoplasms 08/2022 - 09/2009
25	Lymphatic Metastasis 08/2022 - 02/2004
24	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 10/2006
20	Transitional Cell Carcinoma 04/2014 - 01/2002
18	Margins of Excision 12/2021 - 06/2004
17	Carcinoma in Situ 01/2017 - 09/2006
13	Disease Progression 01/2022 - 02/2004
9	Hematuria 12/2021 - 07/2010
8	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019 - 03/2011
6	Adenocarcinoma 11/2018 - 05/2007
6	Shock 07/2011 - 04/2002
5	Kidney Neoplasms (Kidney Cancer) 12/2020 - 08/2012
5	Infections 09/2018 - 11/2003
5	Extranodal Extension 10/2014 - 06/2004
5	Carcinogenesis 06/2014 - 11/2007
5	Obesity 01/2014 - 05/2008
4	Pain (Aches) 12/2019 - 09/2009
4	Necrosis 01/2017 - 11/2015
3	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 06/2021 - 01/2020
3	Hydronephrosis 01/2021 - 01/2011
3	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2021 - 11/2005
3	Fatigue 01/2021 - 10/2012
3	Testicular Neoplasms (Testicular Cancer) 01/2018 - 11/2002
3	Hypertension (High Blood Pressure) 09/2015 - 11/2003
3	Diabetes Mellitus 08/2014 - 12/2013
3	Urolithiasis 07/2011 - 06/2008
3	Hemorrhage 08/2005 - 06/2002
2	Testicular Germ Cell Tumor 04/2021 - 01/2021
2	Cicatrix (Scar) 01/2021 - 09/2008

Drug/Important Bio-Agent (IBA)

64	Biomarkers (Surrogate Marker)IBA 08/2022 - 11/2005
21	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 06/2004
14	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2007
14	nuclear matrix protein 22IBA 04/2016 - 05/2005
13	Tumor Biomarkers (Tumor Markers)IBA 11/2021 - 01/2002
12	Biological ProductsIBA 01/2021 - 04/2007
11	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 06/2008
10	SurvivinIBA 11/2015 - 02/2004
9	Phenobarbital (Luminal)FDA Link 01/2022 - 01/2019
8	Pharmaceutical PreparationsIBA 02/2022 - 06/2012
7	5-aminolevulinic acid hexyl ester FDA Link 01/2022 - 01/2018
6	LipidsIBA 06/2022 - 12/2015
6	Messenger RNA (mRNA)IBA 12/2021 - 08/2014
6	DNA (Deoxyribonucleic Acid)IBA 11/2019 - 07/2011
6	CyclinsIBA 11/2016 - 12/2006
5	EnzymesIBA 11/2019 - 03/2011
4	AndrogensIBA 01/2020 - 08/2013
4	Finasteride (Propecia)FDA LinkGeneric 05/2016 - 03/2005
4	Cyclin EIBA 01/2015 - 03/2011
3	PlatinumIBA 01/2022 - 10/2011
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 04/2015
3	Immune Checkpoint InhibitorsIBA 10/2021 - 01/2017
3	RNA (Ribonucleic Acid)IBA 04/2021 - 08/2017
3	MicroRNAs (MicroRNA)IBA 04/2021 - 12/2015
3	Indicators and Reagents (Reagents)IBA 01/2020 - 08/2010
3	hydrogen sulfite (bisulfite)IBA 11/2019 - 07/2011
3	Glucose (Dextrose)FDA LinkGeneric 11/2019 - 09/2017
3	Caveolin 1IBA 01/2019 - 05/2007
3	Methotrexate (Mexate)FDA LinkGeneric 04/2016 - 06/2008
3	Vinblastine (Vinblastine Sulfate)FDA Link 04/2016 - 06/2008
3	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2016 - 06/2008
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2015 - 07/2013
3	AntigensIBA 04/2015 - 09/2013
3	TOR Serine-Threonine KinasesIBA 01/2015 - 03/2013
3	Metformin (Glucophage)FDA LinkGeneric 08/2014 - 12/2013
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 07/2011 - 03/2007
3	Hemostatics (Antihemorrhagics)IBA 08/2005 - 06/2002
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 11/2022 - 11/2008
2	enfortumab vedotinIBA 02/2022 - 01/2021
2	Immunoconjugates (Immunoconjugate)IBA 02/2022 - 01/2021
2	Carrier Proteins (Binding Protein)IBA 01/2022 - 08/2014
2	Protein Isoforms (Isoforms)IBA 01/2022 - 01/2019
2	AntibodiesIBA 01/2022 - 12/2017
2	Hemoglobins (Hemoglobin)IBA 11/2021 - 01/2020

Therapy/Procedure

112	Cystectomy 08/2022 - 09/2005
71	Therapeutics 01/2022 - 06/2004
59	Nephroureterectomy 11/2021 - 07/2008
38	Lymph Node Excision (Lymph Node Dissection) 06/2021 - 11/2002
35	Drug Therapy (Chemotherapy) 04/2022 - 12/2006
30	Neoadjuvant Therapy 01/2022 - 10/2006
30	Prostatectomy (Retropubic Prostatectomy) 01/2021 - 06/2004
28	Adjuvant Chemotherapy 01/2021 - 10/2006
20	Radiotherapy 11/2021 - 02/2006
17	Nephrectomy 01/2021 - 04/2004
12	Immunotherapy 01/2022 - 10/2012
7	Lithotripsy (Extracorporeal Shockwave Lithotripsy) 12/2012 - 04/2002
6	Transurethral Resection of Bladder 01/2021 - 11/2016
5	Radiofrequency Ablation 01/2016 - 12/2003
4	Length of Stay 01/2020 - 11/2002
3	Aftercare (After-Treatment) 01/2021 - 05/2006
3	Adjuvant Radiotherapy 08/2017 - 10/2006
3	Chemoprevention 02/2011 - 08/2006
3	Operative Surgical Procedures 09/2009 - 11/2004
3	Lasers (Laser) 08/2007 - 06/2002
2	Orchiectomy (Orchidectomy) 04/2021 - 01/2021
2	Solid-State Lasers 01/2021 - 06/2002